Answers are grounded in this paper and cite their sources.
Competitive inhibitors of either α-galactosidase (α-Gal) or β-galactosidase (β-Gal) with high affinity and selectivity have been accessed by exploiting aglycone interactions with conformationally locked sp(2)-iminosugars. Selected compounds were profiled as potent pharmacological chaperones for mutant lysosomal α- and β-Gal associated with Fabry disease and GM(1) gangliosidosis.
No takes yet. Share an insight, caveat, or question.
Aguilar‐Moncayo et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: